Wells Fargo
LXEO icon

Wells Fargo’s Lexeo Therapeutics LXEO Stock Holding History

Wells Fargo’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$276K Buy
59,365
+34,372
+138% +$186K ﹤0.01% 4992
2026
Q1 		$143K Sell
24,993
-45,743
-65% -$324K ﹤0.01% 4910
2025
Q4 		$702K Buy
70,736
+51,474
+267% +$470K ﹤0.01% 4224
2025
Q3 		$128K Buy
19,262
+3,937
+26% +$19K ﹤0.01% 5187
2025
Q2 		$61.6K Buy
15,325
+3,916
+34% +$12.9K ﹤0.01% 5440
2025
Q1 		$39.6K Buy
11,409
+253
+2% +$1.12K ﹤0.01% 5474
2024
Q4 		$73.4K Buy
11,156
+3,714
+50% +$29.3K ﹤0.01% 5352
2024
Q3 		$67.3K Buy
7,442
+4,101
+123% +$48.9K ﹤0.01% 5231
2024
Q2 		$53.6K Sell
3,341
-28
-0.8% -$407 ﹤0.01% 5268
2024
Q1 		$52.8K Buy
3,369
+3,297
+4,579% +$51.6K ﹤0.01% 5236
2023
Q4 		$966 Buy
+72
New +$894 ﹤0.01% 6232

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Wells Fargo's LXEO Position: Q2 2026 in Review

Wells Fargo increased its Lexeo Therapeutics (LXEO) stake by 138% in Q2 2026, buying an estimated $186K and bringing the position to 59,365 shares worth $276K. The position accounts for ﹤0.01% of the portfolio, ranked #4992.

Wells Fargo first reported a position in LXEO in Q4 2023 and has held it in 11 quarters since. The position peaked at $702K in Q4 2025. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Wells Fargo held 59,365 shares of Lexeo Therapeutics worth $276K as of Q2 2026.
  • Wells Fargo bought 34,372 Lexeo Therapeutics shares in Q2 2026, an estimated $186K.
  • Lexeo Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4992 holding.
  • Wells Fargo first reported a position in Lexeo Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Wells Fargo's Lexeo Therapeutics position peaked at $702K in Q4 2025.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.